Consistently, SH-4-54 or STAT5-IN-1 treatment in vivo rescued tumor growth inoculated in Rig-I–/– mice (Figure 7J and Supplemental Figure 7, I–K), thus implicating a functional contribution of STAT5 overactivation to the enhanced antitumor effect of Rig-I–/– CD8+ T cells. This evidence concerns the gene CD8A and neoplasm.